Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Immune response monitoring in patients with hemophilia treated with gene therapy

Priyanka Raheja • 12 Jul 2022
ISTH 2022
Hemophilia Non-Malignant

Priyanka Raheja, MBBS, MD, Royal London Hospital, London, UK, talks on immune response monitoring in patients with hemophilia treated with gene therapy, emphasizing the importance of this practice to identify patients that need to be treated with steroids to avoid a loss in transgene expression. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

Disclosures

Consultant: Pfizer, Sobi, Idogen, Takeda

More from Priyanka Raheja

0:30
Safety & efficacy of TPO-RAs in elderly patients with ITP
Priyanka Raheja • 12 Jul 2022
0:54
ISTH highlights: meeting in person, non-factor replacement therapies & bleeding disorders in women
Priyanka Raheja • 12 Jul 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals